No treatment available today can completely eliminate chronic hepatitis B virus (HBV) from the body, but a growing number of patients are achieving what researchers call a “functional cure,” meaning the virus is suppressed to the point where the immune system keeps it in check without ongoing medication. Functional cure is defined by the sustained loss of hepatitis B surface antigen (HBsAg), a marker long considered the holy grail of HBV treatment. With current therapies, this outcome remains uncommon, but a wave of experimental drugs and combination strategies is pushing those numbers higher, and the science behind why the virus is so stubborn has become much clearer in the past decade.
What “Cure” Actually Means in Hepatitis B
The word “cure” gets used in two very different ways in HBV research, and the distinction matters. A sterilizing cure would mean every trace of HBV DNA is gone from the body, including the viral DNA that has physically woven itself into human chromosomes. No drug or combination of drugs can reliably do this yet. A functional cure, on the other hand, means HBsAg disappears from the blood and stays undetectable, HBV DNA drops below measurable levels, and liver enzymes return to normal. The virus may still lurk at very low levels, but the immune system holds it in check, much like what happens in people who naturally clear an acute infection. Expert consensus treats HBsAg loss as the practical endpoint because it is linked to dramatically improved long-term outcomes, including far lower rates of liver cancer and cirrhosis.1PubMed. Roadmap to functional cure of chronic hepatitis B: An expert consensus
Why the Virus Is So Difficult to Eliminate
Hepatitis B is uniquely hard to eradicate because it establishes two separate reservoirs inside liver cells. The first is a small, ring-shaped piece of DNA called covalently closed circular DNA, or cccDNA, which sits in the nucleus and acts as a self-sustaining template for producing new virus. Current antiviral drugs suppress viral replication but do not directly destroy cccDNA, so it quietly persists even during treatment.2PubMed. Chronic hepatitis B virus persistence: Mechanisms, consequences and implications for achieving cure
The second reservoir is integrated DNA, fragments of HBV that have been stitched permanently into the liver cell’s own chromosomes. Researchers have shown that in patients taking standard antiviral pills, the cccDNA-driven production of surface antigen can drop over time, but integrated DNA picks up the slack and keeps pumping out HBsAg on its own.3PubMed Central. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment In some patients with low viral loads, integrated DNA was responsible for HBsAg production in virtually all liver cells, even though the amount of cccDNA was too low to account for it.4PubMed. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load This dual-reservoir problem explains why just suppressing viral replication is not enough. Any cure strategy has to deal with both sources of viral protein.
What Current Treatments Can and Cannot Do
The backbone of chronic hepatitis B treatment is a class of antiviral pills called nucleoside or nucleotide analogues (NAs), such as entecavir and tenofovir. These drugs are excellent at blocking viral replication, driving HBV DNA in the blood to undetectable levels in most patients. But they do not eliminate cccDNA or integrated DNA, and most patients require lifelong therapy. The rate of functional cure on NAs alone is extremely low.5PubMed Central. Cessation of Nucleoside/Nucleotide Analogue Therapy in Chronic Hepatitis B HBeAg-Negative Patients
The other established option, pegylated interferon alpha (PEG-IFN-α), works differently. Rather than just blocking replication, it rallies the immune system to fight the virus, which is why it can produce a functional cure in some patients. The catch is that HBsAg loss with PEG-IFN-α occurs in only about 5% of treated individuals, and the drug comes with significant side effects including flu-like symptoms, fatigue, and mood changes that make it hard for many patients to tolerate a full course.6PubMed. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy Patients who do achieve functional cure on PEG-IFN-α show lasting immune improvements, including stronger virus-specific T cells and B cells that help maintain long-term control.7PubMed. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB
Neither drug alone, then, is a reliable path to cure for most patients. NAs keep the virus quiet but don’t finish the job. PEG-IFN-α finishes the job occasionally but at a cost most patients find difficult to bear. The limitations of both have driven a massive push toward new drug classes and combination strategies.
New Drugs Targeting the Virus Directly
Several drug classes now in clinical development aim to do things that NAs and interferon cannot. They attack the virus at different stages of its life cycle, and the eventual goal is to stack them together for a multipronged assault.
- RNA interference agents: Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are designed to intercept and destroy HBV messenger RNA before it can be translated into viral proteins like HBsAg. By cutting off the supply of surface antigen, these drugs can unmask the virus to the immune system.8PubMed Central. Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects Laboratory studies with locked nucleic acid antisense molecules have shown they can reduce both HBsAg and another viral marker, HBeAg, in infected human liver cells.9Molecular Therapy Nucleic Acids. Locked Nucleic Acid-Based Antisense Oligonucleotides Targeting Hepatitis B Virus RNA Efficiently Reduce Viral Viremia and Antigenemia In Vivo
- Capsid assembly modulators: HBV packages its genetic material inside a protein shell called a capsid. Capsid assembly modulators (CAMs) bind to the building blocks of this shell and cause it to assemble incorrectly, preventing new viral particles from forming.10PubMed Central. Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives One subclass of these drugs, called heteroaryldihydropyrimidines, can even distort and break apart capsids that have already formed.11eLife. Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids Resistance mutations can emerge, but research suggests that when both normal and mutant virus proteins are present in a cell, the drug-sensitive version dominates the response, keeping CAMs effective.12PLOS Pathogens. HBV capsid assembly modulators differentially modulate the assembly of wild-type and drug-resistant core protein chimeric nucleocapsids and empty capsids
- Entry inhibitors: Bulevirtide blocks the virus from entering liver cells by plugging the receptor HBV uses to get in. It is already approved in some countries for hepatitis D (a virus that piggybacks on HBV), and researchers are exploring its potential in HBV as well.13PubMed Central. Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP Entry inhibitors would not clear virus already inside cells, but they could prevent new cells from becoming infected, shrinking the reservoir over time.
- Nucleic acid polymers: These synthetic molecules interfere with the assembly and release of subviral particles, the decoy HBsAg shells the virus floods the bloodstream with. In animal studies, specific nucleic acid polymers reduced circulating surface antigen and, encouragingly, also lowered intracellular cccDNA levels.14PubMed Central. Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy
None of these drug classes has yet been approved for chronic hepatitis B on its own, but most are in phase II or III clinical trials. Their real promise lies in combination regimens rather than solo use.
Waking Up the Immune System
Chronic hepatitis B is, at its core, a disease of immune failure. The virus does not kill liver cells directly so much as it exhausts the immune cells that should be clearing the infection. Rebuilding that immune response is widely considered essential to any cure strategy.
Therapeutic vaccines aim to re-educate the immune system by presenting viral proteins in a way that triggers a stronger, more focused response than the body achieved on its own.15PubMed Central. Therapeutic vaccination for treatment of chronic hepatitis B Unlike prophylactic vaccines given to prevent infection, these are designed for people who are already chronically infected. Multiple candidates are in clinical testing, often combined with other drugs.
Toll-like receptor (TLR) agonists are small molecules that activate specific alarm sensors on immune cells. An oral TLR7 agonist tested in patients on standard antiviral therapy boosted both T-cell and natural killer cell responses against HBV, though it did not significantly lower HBsAg levels by itself during a 12-week course.16PubMed. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues A TLR8 agonist called selgantolimod fared somewhat better in a phase II trial: it produced modest reductions in HBsAg and HBeAg, with about 5% of participants actually losing HBsAg entirely and about 16% losing HBeAg.17PubMed. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression Those numbers are modest, but the thinking is that TLR agonists may work best as one piece of a larger combination.
Immune checkpoint inhibitors, borrowed from cancer immunotherapy, represent another frontier. In chronic HBV, virus-specific T cells become “exhausted,” partly because the virus upregulates immune brake signals like PD-1 on their surface. Blocking the PD-1/PD-L1 pathway has shown it can reinvigorate these worn-out T cells in laboratory and early clinical settings.18PubMed Central. PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B The major concern is safety: releasing the brakes on the immune system in a liver already prone to inflammation could trigger severe hepatitis flares. Trials are proceeding cautiously, and checkpoint inhibitors are generally being tested at lower doses than those used in cancer, or only in patients whose viral load is well controlled by NAs.19PubMed. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection
Gene Editing and the Dream of Destroying cccDNA
If cccDNA is the root of the problem, why not cut it apart? That is the rationale behind using CRISPR-Cas9 gene-editing technology against HBV. Researchers have delivered CRISPR components to infected liver cells and shown they can introduce mutations into cccDNA, disrupting the virus’s ability to replicate.20PubMed Central. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants In mice with humanized livers infected with HBV, CRISPR treatment produced detectable mutations at viral target sites, though the editing efficiency was low, affecting less than 1% of viral DNA copies.21PubMed Central. CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice
Several practical obstacles remain. One is delivery: getting the editing machinery into enough liver cells to make a meaningful dent. Another is that HBV DNA can be chemically modified (methylated) in ways that reduce how well the CRISPR system can cut it, although higher doses of the editing tool can partially overcome this.22Molecular Therapy: Nucleic Acids. Transient delivery of CRISPR-Cas9 ribonucleoproteins promotes resolution of hepatitis B virus infection And the integrated DNA scattered throughout human chromosomes raises off-target safety concerns: you would need CRISPR to hit viral sequences without accidentally damaging nearby human genes. Gene editing for HBV remains firmly in preclinical research. No one is receiving it as treatment yet, but it represents one of the few approaches that could theoretically achieve a sterilizing cure.
Combination Strategies and Where the Field Stands
The consensus among researchers is that no single drug will cure chronic hepatitis B. The path forward almost certainly involves combinations, much as HIV treatment requires multiple drugs working on different targets. The most promising approach so far pairs an RNA interference agent, which knocks down HBsAg levels, with an immune-boosting therapy like PEG-IFN-α or a TLR agonist. The logic is straightforward: lower the flood of surface antigen that shields the virus from immune attack, then give the immune system a push to finish the job.
Phase II trials using this sequential strategy have achieved HBsAg loss in roughly 15% to 30% of participants, a major improvement over the approximately 5% rate seen with PEG-IFN-α alone.23Hepatoma Research. Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Those numbers are from mid-stage trials and will need confirmation in larger studies, but they represent a genuine step change. Other combinations being explored include NAs paired with capsid assembly modulators, checkpoint inhibitors layered on top of standard antivirals, and therapeutic vaccines combined with RNA-silencing agents. Dozens of trials are running simultaneously, and the landscape shifts every few months as new data emerge.
What Functional Cure Means for Long-Term Health
Achieving functional cure is not just an academic milestone. Patients who lose HBsAg see a dramatic drop in the risk of the most feared complications of chronic hepatitis B. A systematic review and meta-analysis found that HBsAg loss was associated with lower rates of cirrhosis, liver failure, liver-related death, and death from any cause compared to patients who remained HBsAg-positive.24PubMed. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B One analysis estimated that HBsAg loss is tied to roughly a 90% reduction in liver cancer incidence, with five-year cancer rates consistently below 2%.25iLIVER. Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications
The risk does not drop to zero, though. Patients who already had significant fibrosis or cirrhosis before achieving functional cure still carry some residual cancer risk, so continued screening with imaging is recommended even after HBsAg loss. And because integrated HBV DNA remains in liver cells, there is a theoretical basis for very-long-term vigilance even after the immune system has taken over. Still, for the vast majority of patients, functional cure is the closest thing available to putting the disease behind them.
Tracking Progress Toward Cure With New Biomarkers
Knowing whether a patient is moving toward functional cure, or whether a new drug is working, requires more than just measuring HBsAg levels. Researchers are validating newer blood markers that offer a more detailed picture of what the virus is doing inside the liver. Two of the most promising are hepatitis B core-related antigen (HBcrAg), which reflects the activity of cccDNA without requiring a liver biopsy, and serum HBV RNA, which indicates whether the virus’s internal replication machinery is still active.26PubMed Central. New Biomarkers of Chronic Hepatitis B Both markers can help predict which patients will maintain viral control after stopping antiviral pills.
That said, a recent meta-analysis found that HBV RNA and HBcrAg are somewhat less accurate than HBsAg-based markers for predicting who will achieve functional cure on PEG-IFN-α therapy.27PubMed Central. Traditional and Novel Virologic Markers for Functional Cure and HBeAg Loss with Pegylated Interferon in Chronic Hepatitis B: A Systematic Review and Meta-analysis In practice, clinicians are likely to use a panel of markers rather than relying on any single test, tracking how they change over the course of treatment to gauge whether the patient is on a trajectory toward cure.
Stopping Antivirals on Purpose
One counterintuitive strategy gaining traction is deliberately stopping NA therapy in carefully selected patients. The idea is that when the antiviral drug is withdrawn, a controlled flare of viral replication occurs, and this reactivation jolts the immune system into mounting a more effective response. In some patients, the flare is followed by immune consolidation and eventual HBsAg loss.5PubMed Central. Cessation of Nucleoside/Nucleotide Analogue Therapy in Chronic Hepatitis B HBeAg-Negative Patients
In one long-term follow-up study, the eight-year rate of HBsAg loss after stopping NAs was about 20% in patients who had originally been HBeAg-positive and about 33% in HBeAg-negative patients. Patients with lower HBsAg levels at the time they stopped treatment had the best odds: among HBeAg-negative patients whose HBsAg was below 200 IU/mL at the end of treatment, the eight-year HBsAg loss rate reached roughly 69%.28PubMed. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients This is not a risk-free strategy. Viral rebound can sometimes trigger severe hepatitis flares, so treatment cessation is generally only considered in non-cirrhotic patients under close monitoring. But for the right patient, it may offer a better shot at functional cure than staying on pills indefinitely.
Access and the Global Picture
Even as new treatments advance through trials, the reality for most of the estimated 250 million people living with chronic hepatitis B worldwide is far more basic. The majority live in sub-Saharan Africa and East Asia, where access to even standard NA therapy is limited. Current treatment guidelines are complex and lack global consensus, which can hamper implementation in resource-limited settings.29Taylor & Francis Online (Expert Review of Anti-infective Therapy). Global importance of new treatment strategies to efforts to control hepatitis B virus PEG-IFN-α, the only approved drug with a meaningful functional cure rate, requires regular injections, blood monitoring, and management of side effects, all of which demand healthcare infrastructure that many affected communities lack.
If the combination strategies currently in trials prove effective, their accessibility will determine whether functional cure remains an achievement limited to well-resourced clinics or becomes a realistic goal for patients everywhere. Oral drugs with short treatment courses and minimal monitoring requirements would be transformative. Some of the RNA interference agents now in trials are given as infrequent subcutaneous injections, which is a step in the right direction, but cost and cold-chain logistics remain open questions. The science of curing hepatitis B has advanced enormously; the infrastructure to deliver a cure globally has not kept pace.